Levodopa is the most powerful drug available to treat the symptoms of Parkinson disease, and almost all patients with the disease will eventually need to take it. But there has long been controversy about when it should be started, in part because of concern that the medicine itself might cause further damage to the brain cells that are impaired in this disease. To resolve the controversy, a Columbia University scientist led a team of experts from the Parkinson Study Group to study levodopa’s effect on the rate of progression of the disease.
The study, reported in the December 9 issue of The New England Journal of Medicine, showed not only that levodopa does not appear to worsen the disease, but that it may actually slow its progression. A total of 38 Parkinson Study Group sites across the U.S. and Canada conducted this multi-center, placebo-controlled, double-blind clinical trial involving 361 newly diagnosed Parkinson disease patients.
Stanley Fahn, M.D., professor of neurology at Columbia University Medical Center, was the principal investigator of the study. “Although there is still uncertainty on how to interpret the study and further investigation will be necessary to prove levodopa’s value beyond reasonable doubt, we found that levodopa did not accelerate the pace of Parkinson disease,” said Dr. Fahn. “Now patients can feel more secure about the drug and may wish to start it sooner rather than later.”
Karen Zipern | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy